Program
NP-G2-044
Also written as “NP-G2-044 Monotherapy” and “NP-G2-044 Combination therapy”.
Its studies are mostly in Ovarian Neoplasms · Breast Neoplasms, led by Novita Pharmaceuticals.
Furthest: phase 3, since Jul 31, 20253 company-led studies, 1 open or runningNext primary completion: Oct 25, 2028 (phase 3)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Novita Pharmaceuticals | 31 open or running | phase 3since Jul 31, 2025 | Jun 23, 2017 | Oct 25, 2028phase 3 · NCT07109414 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jun 23, 2017First study: phase 1 study in Breast NeoplasmsFirst studyNCT03199586 · 23 enrolled · United States
- Jul 30, 2021Phase 2 study in Advanced or Metastatic Solid Tumor MalignanciesNCT05023486 · 121 enrolled · United States
- Jul 31, 2025Phase 3 study in Ovarian NeoplasmsNCT07109414 · 380 enrolled · United States
Ahead
- Oct 25, 2028Primary completion: phase 3 study in Ovarian NeoplasmsNCT07109414
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07109414Ovarian Neoplasms · United States | 3 | Active, not recruiting | Oct 25, 2028 | 380 |
| NCT05023486Advanced or Metastatic Solid Tumor Malignancies · United States | 2 | Completed | Jun 30, 2026 | 121 |
| NCT03199586Breast Neoplasms · United States | 1 | Completed | May 7, 2020 | 23 |
How it is read
Names in the registry
- “NP-G2-044”, 2 entries
- “NP-G2-044 Monotherapy”, 1 entry
- “NP-G2-044 Combination therapy”, 1 entry
Conditions, from the studies’ own filings
- Ovarian Neoplasms, 1 study
- Breast Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.